ACM
SAGE

ADAR1 Capital Management’s Sage Therapeutics SAGE Stock Holding History

ADAR1 Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-721,599
Closed -$6.58M – 254
2025
Q2 		$6.58M Sell
721,599
-20,896
-3% -$154K 1.01% 26
2025
Q1 		$5.9M Buy
742,495
+723,295
+3,767% +$5.3M 1.1% 25
2024
Q4 		$104K Sell
19,200
-32,450
-63% -$198K 0.02% 179
2024
Q3 		$373K Buy
+51,650
New +$473K 0.06% 129

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

ADAR1 Capital Management's SAGE Position: Q3 2025 in Review

ADAR1 Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 721,599 shares — an estimated $6.58M sold.

ADAR1 Capital Management first reported a position in SAGE in Q3 2024 and held it in 4 quarters. The position peaked at $6.58M in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • ADAR1 Capital Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 721,599 Sage Therapeutics shares in Q3 2025, an estimated $6.58M.
  • ADAR1 Capital Management first reported a position in Sage Therapeutics in Q3 2024 and held it in 4 quarters.
  • ADAR1 Capital Management's Sage Therapeutics position peaked at $6.58M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on ADAR1 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.